Alice Melao,  —

Articles by Alice Melao

Russia Approves Its Local Company BIOCAD’s Infliximab Biosimilar for Ankylosing Spondylitis

Russian regulators have approved the Russian company BIOCAD’s infliximab biosimilar as a treatment for rheumatoid arthritis and ankylosing spondylitis. The approval was based on extensive preclinical-trial studies and trial results showing that BIOCAD is similar to Janssen’s Remicade, the company said. BIOCAD experts the results to support its product’s approval…

Biologic DMARDs Do Not Prevent Spinal Fractures in AS Patients, Swedish Study Shows

Use of biological disease-modifying antirheumatic drugs (bDMARDs) does not prevent spinal fractures in patients with ankylosing spondylitis, according to a Swedish population-based study. Findings from the study, “Do biological disease-modifying antirheumatic drugs reduce the spinal fracture risk related to ankylosing spondylitis? A longitudinal multiregistry matched cohort study,”…

Top-line Data Awaited in Phase 2b Trial of Alternative to Naproxen as Painkiller

Antibe Therapeutics has fully enrolled a trial comparing the gastrointestinal safety of investigative compound ATB-346 with naproxen, a nonsteroidal anti-inflammatory drug (NSAID). The Phase 2b trial is running as scheduled, and the company plans to release top-line data within six weeks. Naproxen, sold under the brand names Aleve, Naprosyn, and others, is one of the…

Obesity Can Make Axial Spondyloarthropathy Worse, Irish Study Finds

Obesity can make the spinal arthritis disease axial spondyloarthropathy worse, Irish researchers report. Obese patients are likely to have worse symptoms, less physical function, and lower quality of life, according to a team at St. James’s Hospital in Dublin. Overall, two-thirds of axSpa patients are either overweight or obese, the study…